Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Vir Biotechnology Inc (NASDAQ: VIR) closed at $6.14 down -5.25% from its previous closing price of $6.48. In other words, the price has decreased by -$5.25 from its previous closing price. On the day, 2.84 million shares were traded. VIR stock price reached its highest trading level at $6.75 during the session, while it also had its lowest trading level at $6.0.
Ratios:
For a deeper understanding of Vir Biotechnology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.25 and its Current Ratio is at 7.25. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In the most recent recommendation for this company, Evercore ISI on September 03, 2025, initiated with a Outperform rating and assigned the stock a target price of $12.
On August 27, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $14.
JP Morgan Downgraded its Overweight to Neutral on January 29, 2024, whereas the target price for the stock was revised from $23 to $9.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 01 ’25 when SVF Endurance (Cayman) Ltd sold 191,854 shares for $5.98 per share. The transaction valued at 1,147,786 led to the insider holds 13,728,924 shares of the business.
SATO VICKI L sold 22,000 shares of VIR for $132,070 on Dec 01 ’25. The Director now owns 1,188,391 shares after completing the transaction at $6.00 per share. On Nov 26 ’25, another insider, SVF Endurance (Cayman) Ltd, who serves as the 10% Owner of the company, sold 127,938 shares for $6.39 each. As a result, the insider received 817,652 and left with 13,982,271 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 854227648 and an Enterprise Value of 447889696. For the stock, the TTM Price-to-Sale (P/S) ratio is 50.67 while its Price-to-Book (P/B) ratio in mrq is 1.07. Its current Enterprise Value per Revenue stands at 26.565 whereas that against EBITDA is -0.876.
Stock Price History:
The Beta on a monthly basis for VIR is 1.38, which has changed by -0.120759845 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, VIR has reached a high of $14.45, while it has fallen to a 52-week low of $4.16. The 50-Day Moving Average of the stock is 2.64%, while the 200-Day Moving Average is calculated to be 9.37%.
Shares Statistics:
For the past three months, VIR has traded an average of 1.55M shares per day and 1858900 over the past ten days. A total of 139.02M shares are outstanding, with a floating share count of 94.03M. Insiders hold about 32.42% of the company’s shares, while institutions hold 54.22% stake in the company. Shares short for VIR as of 1764288000 were 11110359 with a Short Ratio of 7.19, compared to 1761868800 on 9581029. Therefore, it implies a Short% of Shares Outstanding of 11110359 and a Short% of Float of 12.86.
Earnings Estimates
The company has 8.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.61, with high estimates of -$0.45 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$3.02 and -$3.62 for the fiscal current year, implying an average EPS of -$3.36. EPS for the following year is -$2.91, with 9.0 analysts recommending between -$2.3 and -$3.63.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $19.91M this quarter.It ranges from a high estimate of $66M to a low estimate of $240k. As of. The current estimate, Vir Biotechnology Inc’s year-ago sales were $12.37MFor the next quarter, 7 analysts are estimating revenue of $2.37M. There is a high estimate of $4.5M for the next quarter, whereas the lowest estimate is $310k.
A total of 9 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $70.5M, while the lowest revenue estimate was $4.73M, resulting in an average revenue estimate of $20.8M. In the same quarter a year ago, actual revenue was $74.2MBased on 9 analysts’ estimates, the company’s revenue will be $9.68M in the next fiscal year. The high estimate is $18.1M and the low estimate is $1.22M.
